(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of -1.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.01%.
Puma Biotechnology's revenue in 2026 is $231,825,000.On average, 3 Wall Street analysts forecast PBYI's revenue for 2026 to be $11,706,575,733, with the lowest PBYI revenue forecast at $11,247,494,331, and the highest PBYI revenue forecast at $12,050,886,784. On average, 3 Wall Street analysts forecast PBYI's revenue for 2027 to be $11,548,378,763, with the lowest PBYI revenue forecast at $11,095,501,165, and the highest PBYI revenue forecast at $11,888,036,962.
In 2028, PBYI is forecast to generate $11,390,181,794 in revenue, with the lowest revenue forecast at $10,943,507,998 and the highest revenue forecast at $11,725,187,141.